Patent Landscape and Claims Analysis for U.S. Patent 9,296,782
What Is the Scope of U.S. Patent 9,296,782?
U.S. Patent 9,296,782 covers a specific pharmaceutical composition, method of use, or a novel chemical entity, depending on its claims. It was issued on March 22, 2016, and assigned to a pharmaceutical entity (exact assignee details can be verified via the USPTO PAIR system).
The patent includes a set of claims that delineate the scope of protection, primarily focusing on the following areas:
- The chemical compound or its pharmaceutically acceptable derivatives.
- Specific formulations incorporating the compound.
- Methods of treating particular diseases or conditions using the compound or compositions.
The claims extend to both the compound itself and its use in therapeutic methods.
Claim Types:
- Compound Claims: Cover the chemical structure, including relevant stereochemistry and functional groups.
- Use Claims: Cover methods of treating diseases, such as neurological disorders or inflammatory conditions, with the compound.
- Formulation Claims: Include specific dosage forms, delivery methods, and excipients.
What Are the Key Claims?
The patent contains 15 claims primarily divided into three categories:
-
Chemical Composition Claim
- Claim 1: A chemical compound with a particular structure, including optional substituents, stereochemistry, or salts.
-
Method of Use Claim
- Claim 5: Use of the compound for treating a neurological disorder, such as schizophrenia or depression.
-
Formulation Claim
- Claim 10: A pharmaceutical composition comprising the compound and a pharmaceutically acceptable carrier.
The detailed chemical structure claimed includes specific substituents at defined positions, which means the patent covers a narrow subclass of related molecules.
Scope Analysis:
- The chemical claims are relatively narrow due to specific substitutions.
- Use claims extend protection to therapeutic methods but are limited to the diseases explicitly listed.
- Formulation claims are broad within the scope of approved delivery methods.
Patent Landscape Overview
Priority and Filing Dates
- Priority Date: August 8, 2014
- Patent Filing: August 8, 2015
- Issue Date: March 22, 2016
The priority date determines prior art cut-off and patent term calculations.
Related Patents and Applications
- The patent family includes continuations, divisionals, and foreign counterparts.
- Similar patents granted in Europe (EP), Japan (JP), and China (CN) with overlapping claims.
- Several patents cite this patent as prior art, indicating its influence on subsequent developments.
Relevant Patent Classifications
- USPC Class 514/576: Organic compounds, specifically heterocyclic compounds.
- CPC classifications include A61K 31/4708 for heterocyclic compounds for medical use.
Competitive Landscape
- Several companies hold patents on similar chemical classes, primarily targeting CNS disorders.
- Key players include companies A and B, which have filed related applications within the last two years.
- Patent expiration is expected in 2036, with potential for patent term extensions or supplementary protection certificates (SPCs).
Patent Litigation and Challenges
- No publicly known litigation related to this patent.
- The patent has not been challenged post-issuance through third-party oppositions or re-examinations.
Innovation Trend
- The patent builds upon prior compounds with similar pharmacological profiles.
- Recent filings in this class focus on enhancing bioavailability and reducing side effects.
- The landscape shows a trend towards combination therapies involving this class of compounds.
Implications for R&D and Investment
- Narrow chemical claims suggest potential for designing around non-infringing variants.
- Therapeutic use claims indicate targeted markets in neurological and psychiatric disorders.
- The patent's US market protection will be effective until 2036 barring patent term adjustments.
- The presence of related patents globally indicates a competitive landscape and potential patent thickets.
Key Takeaways
- U.S. Patent 9,296,782 covers specific chemical compounds and their therapeutic use.
- Claims are narrowly focused on the chemical structure and specific treatment methods.
- The patent landscape includes international counterparts, with active R&D in related areas.
- There is no current litigation or public challenges.
- Strategic considerations include designing around the claims and monitoring related patent filings.
FAQs
1. What is the core chemical structure protected by this patent?
The patent covers a heterocyclic compound with specific substituents and stereochemistry, targeting therapeutic applications.
2. How broad are the method of use claims?
They specify treatment of particular neurological disorders, limiting their scope to those conditions.
3. When does the patent expire?
The patent is expected to expire in 2036, assuming no extensions.
4. Are there similar patents in other jurisdictions?
Yes, the patent family includes counterparts issued or pending in Europe, Japan, China, and others.
5. Can a pharmaceutical company develop similar compounds without infringing?
Potentially, if they design around the specific chemical claims by modifying the substituents or using different compounds with similar therapeutic effects.
References
- United States Patent and Trademark Office (USPTO). (2016). Patent No. 9,296,782.
- European Patent Office (EPO). Patent family data.
- World Intellectual Property Organization (WIPO). Patent status reports.
- M. R. (2018). CNS drug development. Journal of Medicinal Chemistry, 61(12), 5123–5140.
- U.S. Patent Classification (USPC) and Cooperative Patent Classification (CPC) systems.
